This activity is supported by an unrestricted educational grant from Alcon Vision, Johnson & Johnson Vision, and Orasis Pharmaceuticals.
Upon completion of this activity, the participant should be able to:
Jointly Proviced by Evolve Medical Education and The Fundingsland Group
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC (Evolve) and The Fundingsland Group. Evolve is accredited by the ACCME to provide continuing medical education for physicians.
DESIGNATION STATEMENT
Evolve designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+
Iqbal Ike K. Ahmed, MD
Assistant Professor, University of Toronto
Fellowship Director, Glaucoma and Anterior Segment Surgery Fellowship, University of Toronto
Research Director, Kensington Eye Institute, University of Toronto
Division Head, Ophthalmology, Trillium Health Partners, Mississauga, Ontario
Medical Director, Prism Eye Institute
Co-Medical Director, TLC Oakville
Toronto, Canada
Gerd U. Auffarth, MD, PhD, FEBO
Chairman, Department of Ophthalmology, Heidelberg University Eye Hospital
Director (Head), International Vision Correction Research Centre
Director (Head), David J. Apple Center for Ocular Pathology
University-Eye Clinic
Heidelberg, Germany
Brandon D. Ayres, MD
Cornea Service
Wills Eye Hospital
Philadelphia, PA
Daniel H. Chang, MD
Cataract and Refractive Surgeon / Managing Partner
Empire Eye and Laser Center
Bakersfield, CA
Eric D. Donnenfeld, MD
Ophthalmic Consultants of Long Island and Connecticut
Trustee, Dartmouth Medical School
Clinical Professor of Ophthalmology
New York University
New York, NY
Marjan Farid, MD
Director of Cornea, Cataract, and Refractive Surgery
Vice Chair of Ophthalmic Faculty
Clinical Professor of Ophthalmology
Gavin Herbert Eye Institute
University of California, Irvine
Nicole Fram, MD
Managing Partner at Advanced Vision Care in Los Angeles, CA
Clinical Instructor of Ophthalmology
Stein Eye Institute
University of California,Los Angeles
Paul Harasymowycz, MD
Associate Professor, University of Montreal
Medical Director
Bellevue Ophthalmology Clinics and
Montreal Glaucoma Institute
Montreal, Canada
Edward J. Holland, MD
Professor of Ophthalmology
University of Cincinnati
Director of the Cornea Service
Cincinnati Eye institute
Cincinnati, Ohio
Douglas D. Koch, MD
Professor
Allen, Mosbacher, and Law Chair in Ophthalmology
Baylor College of Medicine
Houston, TX
Cathleen M. McCabe, MD
Chief Medical Officer, Eye Health America
Medical Director, The Eye Associates
Bradenton, FL
Constance Okeke, MD, MSCE
Glaucoma & Cataract Specialist
CVP Physicians/Virginia Eye Consultants
Assistant Professor of Ophthalmology
Eastern Virginia Medical School
Norfolk, Virginia
Karolinne M. Rocha, MD, PhD
Assistant Professor of Ophthalmology
Director, Cataract, Cornea and Refractive Surgery
Cataract & Refractive Surgery Fellowship Director
Medical University of South Carolina
Storm Eye Institute
Charleston, South Carolina
Karl G. Stonecipher, MD
Clinical Associate Professor of Ophthalmology
University of North Carolina, Chapel Hill
Associate, Piedmont Eye Surgical and Laser Center
Greensboro, North Carolina
Director, TLC Laser Eye Centers
Greensboro and Raleigh, North Carolina
Elizabeth Yeu, MD
Moderator
Virginia Eye Consultants
Medical Director, CVP Mid-Atlantic
Cornea, Cataract, External Disease and Refractive Surgery
Assistant Professor, Department of Ophthalmology
Eastern Virginia Medical School
Norfolk, Virginia
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Iqbal Ike K. Ahmed, MD, had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Aequus, Aerie Pharmaceuticals, Akorn, Alcon Vision, Allergan, Aquea Health, ArcScan, Bausch Health, Beaver Health, Beaver Visitec, Camras Vision, Carl Zeiss Meditec, CorNeat Vision, Ellex, ELT Sight, ElutiMed, Equinox, Genentech, Glaukos, Gore, InjectSense, Iridex, iStar, Ivantis, Johnson & Johnson Vision, KeLoTec, LayerBio, Leica, Long Bridge Medical, MicroOptx, MST Surgical, Mynosys, New World Medical, Ocular Instruments, Ocular Therapeutix, PolyActiva, Sanoculis, Santen, Science Based Health, Sight Sciences, Smartlens, Stroma, Thea, ViaLase, and Vizzario. Speaker Honoraria: Alcon, Allergan, Carl Zeiss Meditec, Johnson & Johnson Vision, MST Surgical, Mundipharma. Research Grants: Aerie Pharmaceuticals, Alcon Vision, Allergan, Camras, Glaukos, Johnson & Johnson Vision, New World Medical, and Santen.
Gerd U. Auffarth, MD, PhD, FEBO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Carl Zeiss Meditec, Johnson & Johnson Vision. Lecture Fees: Biotech, Carl Zeiss Meditec, Johnson & Johnson Vision, Hoyga, Kowa, Oculentis, Oculus, Rayner, Santen, and Sifi. Travel Fees: Alcon Vision, Carl Zeiss Meditec, Johnson & Johnson Vision, Hoya, Kowa, Oculentis, Rayner, Santen, and Sifi. Research Grants: Acufocus, Johnson & Johnson Vision, Anew, Biotech, Carl Zeiss Meditec, Contamac, Hoya, Kowa, Oculentis, Oculus, PhysIOL, Rayner, Santen, and Sifi.
Brandon D. Ayres, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon Vision, Allergan, Bausch + Lomb, Carl Zeiss Meditec, Dompé, Eyevance, Eyepoint Pharmaceuticals, Glaukos, Gore Surgical, Kala, Omeros, Microsurgical Technology, Mojo, Novartis, Sight Sciences, and TearLab. Speaker’s Bureau: Alcon Vision, Allergan, and Dompé.
Daniel H. Chang, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Carl Zeiss Meditec, Johnson & Johnson Vision, Mynosys, and Omega Ophthalmics. Grant/Research Support: Acufocus, Johnson & Johnson Vision, and Mynosys. Stock/Shareholder: Omega Ophthalmics.
Eric D. Donnenfeld, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Allegro, Allergan, Avellino, Bausch + Lomb, Carl Zeiss Meditec, CorneaGen, Covalent, BVI, Blephex, Dompé, ELT Sight, EyePoint Pharmaceuticals, Foresight, Glaukos, Ivantis, Johnson & Johnson Vision, Kala Pharmaceuticals, Katena, Lacripen, LensGen, Mati Therapeutics, MDBackline, Merck, Mimetogen, Nanowafer, Novabay, Novartis, Novaliq, Ocular Innovations, Oculis, Odyssey, Omega Ophthalmics, Oyster Point Pharma, Pfizer, Pogotec, Ocuhub, Omeros, PRN, RegenerEyes, ReTear, RPS, Shire, Strathspey Crown, Sun Pharmaceutical Industries, Surface, Tarsus, Tearlab, Tearscience, Thea, TLC Laser Centers, Veracity, Versant Ventures, Visionary Venture, and Visus. Stock/Shareholder: Avedro, CorneaGen, Covalent, ELT Sight, EyePoint Pharmaceuticals, Glaukos, Ivantis, Lacripen, LensGen, Mati Therapeutics, MDBackline, Mimetogen, Novabay, Ocuhub, Ocular Innovations, Oculis, Orasis Pharmaceutical, Pogotec, RegenerEyes, ReTear, RPS, Strathspey Crown, Surface, Tarsus, TearLab, Veracity, Versant Ventures, Visionary Ventures, and Visus.
Marjan Farid, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, BioTissue, Carl Zeiss Meditec, CorneaGen, Dompé, Eyepoint Pharmaceuticals, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, and Novartis.
Nicole Fram, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Allergan, CorneaGen, Johnson & Johnson Vision, and Ocular Therapeutics. Grant/Research Support: Alcon Vision, and Allergan. Speaker’s List: Alcon Vision, BVI, CorneaGen, Dompé, MST, and Ocular Therapeutix. Stock/Shareholder: CorneaGen, and Ocular Science.
Paul Harasymowycz, MD, had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Allergan, Aequus Pharmaceuticals, Alcon Vision, Bausch Health, Glaukos, Iridex, Ivantis, Johnson & Johnson Vision, New World Medical, Novartis, Santen, and Thea. Grant/Research Support: Allergan, Bausch Health, Glaukos, Ivantis, Johnson & Johnson Vision, and Thea.
Edward J. Holland, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Abingworth, Aerie Pharmaceuticals, Akros Pharma, Alcon Vision, Aldeyra Therapeutics, Allegro, Allergan, Azura Ophthalmics, BlephEx, BRIM biotech, Carl Zeiss Meditec, Claris Bio, Corneat, CorneaGen, Dompé, Expert Opinion, Eye Point Pharmaceuticals, Glaukos, Hanall, Invirsa, Kala Pharmaceuticals, Mati Therapeutics, Merck, Novartis NIBR, Novartis, Ocular Therapeutix, Ocuphire, Omeros, Oyster Point Pharma, Precise Bio, Prometic Biotherapeutics, ReGentree, Retear, Senju, Shire, Sight Sciences, Slack, Tarsus, TearLab Research, Vomaris, and W.L. Gore and Associates. Grant/Research Support: Alcon Vision, Mati Therapeutics, Novartis, Omeros, Senju, and Shire. Speaker’s Bureau: Alcon Vision, Novartis, Omeros, Senju, and Shire.
Douglas D. Koch, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Carl Zeiss Meditec, Johnson & Johnson Vision, and Perfect Lens. Stock/Shareholder: Ivantis, and Vivior.
Cathleen M. McCabe, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Carl Zeiss Meditec, Eye Point Pharmaceuticals, Ocular Therapeutix, Novartis, Dompé, Bausch + Lomb, Ivantis, Omeros,
and Sight Sciences. Grant/Research Support: Alcon Vision, Allergan, Dompé, Eye Point Pharmaceuticals, Glaukos, Johnson & Johnson Vision,
Ocular Therapeutix, Ivantis, and Novartis. Speakers List: Allergan, Bausch + Lomb, Carl Zeiss Meditec, Dompé, Eye Point Pharmaceuticals, Ivantis, Novartis, Ocular Therapeutix, Omeros, and Sight Sciences. Stock/Shareholder: Engage Technologies and Ivantis.
Constance Okeke, MD, MSCE, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie Pharmaceuticals, Akorn, Alcon Vision, Allergan, Bausch + Lomb, Nova Eye Medical, Eyenovia, Glaukos, Ivantis, MST, Sight Sciences, Sun Pharmaceutical Industries, and Thea. Grant/Research Support: Bausch + Lomb, Glaukos, and Nicox. Speaker’s Bureau: Aerie Pharmaceuticals, Allergan, Bausch + Lomb, MST, and Sun Pharmaceutical Industries. Stock/Shareholder: Mediprint, and Visionology. Other Financial Support: Kugler Publications.
Karolinne M. Rocha, MD, PhD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Allergan, Bausch + Lomb, Carl Zeiss Meditec, Dompé, and Johnson & Johnson Vision.
Karl G. Stonecipher, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Grant/Research Support and Speaker’s Bureau: Acufocus, Alcon Vision, Allergan, Alphaeon, Bausch + Lomb, Espansione, Johnson & Johnson Vision, Greenlight, Kala, Marco, Nidek, Novartis, Presbia, and Refocu. Stock/Shareholder: Alphaeon, Pogotec, and Strathspey Crown.
Elizabeth Yeu, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Allergan, Avedro, Bausch + Lomb, BioTissue, Beaver Visitec, BlephEx, Bruder, Carl Zeiss Meditec, CorneaGen, Dompé, Expert Opinion, EyePoint Pharmaceuticals, Guidepoint, Johnson & Johnson Vision, Kala Pharmaceuticals, Lensar, Merck, Mynosys, Novartis, Ocular Science, Ocular Therapeutix, Ocusoft, Omeros, Oyster Point Pharma, Science Based Health, Shire, Sight Sciences, Sun Pharmaceutical Industries, Surface, Thea, Tarsus, TopCon, TearLab, and Visus Therapeutics. Grant/Research Support: Alcon Vision, BioTissue, Ocular Science, TopCon, and TearLab. Stock/Shareholder: BlephEx, CorneaGen, Melt, Ocular Science, Oyster Point Pharma, and Tarsus.
The Evolve and The Fundingsland Group staff and planners have no financial relationships with commercial interests. Diane Angelucci, writer, and Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group, Cataract & Refractive Surgery Today, Alcon Vision, Johnson & Johnson Vision, and Orasis Pharmaceuticals.
